Therapeutic Antibodies

Question 1

Muromonab-CD3 (OKT3)

Answer 1

Targets CD3. Prevents acute transplant rejection

Question 2

Digoxin Immune Fab

Answer 2

Targets digoxin. Antidote for digoxin intoxication.

Question 3

Infliximab

Answer 3

Targets TNF alpha. Treats rheumatoid arthritis, Seronegative arthropathies (HLA-B27 -> PAIR: psoriatic arthritis, ankylosing spondylitis, IBD (Crohn’s disease or Ulcerative colitis) and Reactive arthritis (Reiter’s syndrome)). Can also treat severe IBD without arthritic component.

Question 4

Adalimumab

Answer 4

Targets TNF alpha. Treats rheumatoid arthritis, Seronegative arthropathies (HLA-B27 -> PAIR: psoriatic arthritis, ankylosing spondylitis, IBD (Crohn’s disease or Ulcerative colitis) and Reactive arthritis (Reiter’s syndrome)). Can also treat severe IBD without arthritic component.

Question 5

Abciximab

Answer 5

Targets Glycoprotein IIa/IIIb. Prevents cardiac ischemia in unstable angina and in patients treated with percutaneous coronary intervention

Question 6

Trastuzumab (Herceptin)

Answer 6

Targets HER2. Treats HER2 overexpressing breast cancers

Question 7

Rituximab

Answer 7

Targets CD20. Treats B-cell non-Hodgkin’s lymphoma.

Question 8

Omalizumab

Answer 8

Targets IgE. Additional treatment for severe asthma.

Question 9

Imatinib (Gleevec)

Answer 9

Targets tyrosine kinase. Has radically improved the treatment and prognosis of CML (chronic myelogenous leukemia).

Question 10

Entanercept

Answer 10

Targets TNF alpha. TNF alpha receptor plus IgG1 Fc. Essentially a decoy receptor for TNF alpha. Treats rheumatoid arthritis, Seronegative arthropathies (HLA-B27 -> PAIR: psoriatic arthritis, ankylosing spondylitis, IBD (Crohn’s disease or Ulcerative colitis) and Reactive arthritis (Reiter’s syndrome)). Can also treat severe IBD without arthritic component.